▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #413 by analyst upside · 2026-10-16
DBVT
DBV Technologies S.A.
Healthcare · Market Cap $573M · P/E 0x
ANALYST PRICE TARGET
+325.4%
implied upside to consensus target
Current Price $9.11
Consensus Target $38.75
Bull Target $54.59
Bear Target $5.72
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
5
Hold
0
Sell
1
52-Week Low $8.85
52-Week High $26.18
YTD Return -52.2%
FUNDAMENTALS
Market Cap $573M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.50
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $5M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.85
52-Week High $26.18
Current Price $9.11
Bear Target $5.72
Bull Target $54.59
● Now $9.11 ● Target $38.75
TRADING DATA
Avg Volume 349K
YTD Return -52.2%
Analyst Count 7
Consensus Buy
Upside to Target +325.4%
Last Updated 2026-10-16

ANALYST SUMMARY

DBV Technologies S.A. (DBVT) is currently trading at $9.11 with a Wall Street consensus price target of $38.75, implying potential upside of 325.4% over the next 12 months. 7 analysts currently cover DBVT, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $54.59, while the most cautious has a target of $5.72.

DBVT operates in the Healthcare sector with a market capitalisation of $573M. The stock is down 52.2% year-to-date and is currently trading near the lower end of its 52-week range of $8.85 – $26.18.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AGEN +294.2%
Agenus Inc.
$302M · P/E 2.8x · Buy
APMD +175.9%
Apnimed, Inc.
$760M · P/E 2.5x · Buy
ZVRA +143.4%
Zevra Therapeutics, Inc.
$610M · P/E 11.2x · Buy
MGTX +180.6%
MeiraGTx Holdings plc
$950M · P/E 11.0x · Buy
ASMB +152.8%
Assembly Biosciences, Inc.
$419M · P/E 19.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for DBVT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens - Reiterated
Market Outperform → Market Outperform 2026-06-30 Building track record
Guggenheim reit
Buy → Buy 2026-05-04 62% win rate (8 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-01 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-03-27 Building track record
Guggenheim reit
Buy → Buy 2026-03-27 62% win rate (8 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-12-17 31% win rate (48 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2025-12-17 40% win rate (10 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2025-12-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
16/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →